AMRI Agrees to New Contract with International Chemical Workers Union.

ALBANY, N.Y. -- Albany Molecular Research, Inc. (NASDAQ: AMRI) has agreed to a new four-year contract with the International Chemical Workers Union Council of the United Food and Commercial Workers Union Local 61-C. The contract covers chemical operators and maintenance technicians at AMRI's large scale manufacturing facility in Rensselaer, New York 

The new contract, which runs through January 10, 2011, provides for wage increases, benefit plan updates and operational effectiveness considerations. The contract was ratified by the union on December 23, 2006. The previous contract was set to expire in January 2007.

"We are pleased to announce this new collective bargaining agreement," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. "I congratulate both of the negotiation teams on a quick and successful resolution to this process. We especially appreciate the willingness of our employees during a time of restructuring at our large scale facilities to negotiate an agreement that considered the interests of all parties, and contribute to corporate wide efforts to find ways to seek improved margins. I want our employees to publicly know that we appreciate their contributions to this process and thank them for their part in helping our Rensselaer operations be more successful going forward."

Jim Glavin, president of the ICWU Local 61-C, added, "The agreement was fair to all parties involved."

AMRI provides scientific services, technologies and products that improve quality of life while delivering excellence, value and maximum return.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.